Emerging as a significant development in the battle against obesity, Retatrutide is attracting considerable buzz. It combines properties of two known GLP-1 binding agonists, liraglutide, and an additional glucose-dependent incretin component. Early patient data have indicated impressive fat decrease in individuals with excessive weight, potentially